The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2022 | Lung cancer genotyping with NGS
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of the impact of EGFR genotyping with next-generation sequencing (NGS) in lung cancer. In addition to the standard mutations PCR techniques such as qRT-PCR, many more mutations such as exon 20 insertion mutations can be detected by NGS. Prof. Popat highlights the significance of detecting the aforementioned mutations as it enables patients who will benefit from novel therapies such as mobocertinib and amivantimab to be identified. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.
